Log in to your Inderes Free account to see all free content on this page.

Xspray Pharma

24.65 SEK

-1.40 %

Less than 1K followers

XSPRAY

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Dividend

Investor consensus

-1.40 %

-2.18 %

-21.62 %

-20.48 %

-48.21 %

-12.86 %

-66.93 %

-77.52 %

-18.38 %

Xspray Pharma is a pharmaceutical company with several product candidates in clinical development that uses the patented HyNap technology to create improved versions of marketed protein kinase inhibitors. The drug candidate Dasynoc® is an amorphous form of dasatinib and is undergoing FDA review for market approval. Xspray Pharma's product portfolio also includes XS003-nilotinib, XS008-axitinib and XS025-cabozantinib.

Market cap

1.03B SEK

Turnover

653.73K SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

6.5.

2026

Interim report Q1'26

12.5.

2026

General meeting '26

5.8.

2026

Interim report Q2'26

All

Press releases

ShowingAll content types

Press release3/11/2026, 2:50 PM

Xspray Pharma: FDA accepts resubmitted application for market approval of Dasynoc® – PDUFA date August 25, 2026

Press release2/26/2026, 2:59 PM

Xspray Pharma re-submits its FDA application for Dasynoc

Regulatory press release2/26/2026, 6:45 AM

Xspray Pharma appoints Blake Leitch as CEO – Per Andersson continues as Chief Scientific Officer (CSO)

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Press release2/17/2026, 7:26 AM

Redeye: Xspray Pharma (Q4 Review): A pivotal year ahead

Regulatory press release2/12/2026, 7:00 AM

Interim Report Fourth Quarter 2025

Press release11/7/2025, 7:52 AM

Redeye: Xspray Pharm (Q3 update) - Two PDUFA dates in 2026

Regulatory press release11/5/2025, 7:00 AM

Interim Report Third Quarter 2025

Press release10/21/2025, 9:45 AM

Xspray Pharma: FDA accepts New Drug Application for XS003 (nilotinib) for the treatment of CML – PDUFA date set for June 18, 2026

Press release10/19/2025, 2:43 PM

Redeye: Xspray Pharma - Update after Dasynoc CRL

Regulatory press release10/10/2025, 8:00 AM

Xspray Pharma’s Nomination Committee for the Annual General Meeting 2026

Regulatory press release10/8/2025, 12:40 AM

Xspray Pharma provides update on the FDA process for Dasynoc – observations at contract manufacturer delay approval

Regulatory press release9/30/2025, 1:55 PM

New number of shares and votes in Xspray Pharma after new share issue

Regulatory press release9/11/2025, 6:00 AM

Xspray’s rights issue oversubscribed – over-allotment issue increased and fully utilized

Regulatory press release8/26/2025, 11:10 AM

First day of trading in subscription rights and BTAs moved to August 27

Regulatory press release8/25/2025, 2:55 PM

Xspray publishes disclosure document regarding rights issue

Regulatory press release8/25/2025, 2:45 PM

Xspray receives additional subscription undertakings of SEK 20 million in the ongoing rights issue

Press release8/19/2025, 6:48 AM

Redeye: Xspray Pharma Q2 2025 - Case defining months ahead

Press release8/19/2025, 6:07 AM

Xspray Pharma Submits XS003 to the FDA – The Company’s Second Product Candidate from the HyNap Platform

Regulatory press release8/15/2025, 6:00 AM

Interim Report Second Quarter 2025

Regulatory press release8/15/2025, 5:50 AM

Xspray resolves on a rights issue of approximately SEK 130 million with an over-allotment issue and carries out debt refinancing

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.